Quick answers
- What is Amoxapine used for?
- The FDA-approved label (Amoxapine, Chartwell RX, LLC, December 18, 2024) says: “Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Amoxapine have a boxed warning?
- Yes. The FDA label for Amoxapine has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Amoxapine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Amoxapine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Amoxapine?
- 2 companies list prescription products of Amoxapine in the FDA NDC Directory, including Chartwell RX, LLC and Actavis Pharma, Inc..
What Amoxapine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.
— FDA label: Amoxapine, Chartwell RX, LLC, effective December 18, 2024. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 8 in the FDA NDC Directory |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Chartwell RX, LLC4 products
- Actavis Pharma, Inc.4 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (2)
- ANDA072879Chartwell Rx · June 28, 1991
- ANDA072691Watson Labs · August 28, 1992
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 197363, 197364, 197365, 197366 |
|---|---|
| SPL set ID of the quoted label | eed5e856-dd7b-4eaa-9dad-508f2bef9328 |
| FDA labels (SPL) | 1 |
| FDA applications | 2 ANDA |
| Active ingredients (FDA) | AMOXAPINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Amoxapine, Chartwell RX, LLC, effective December 18, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →